Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 26 July 1985:
Vol. 229. no. 4711, pp. 395 - 397
DOI: 10.1126/science.2990050
Prev | Table of Contents | Next

Articles

Science, Vol 229, Issue 4711, 395-397
Copyright © 1985 by American Association for the Advancement of Science

articles

Vasopressin-stimulated release of atriopeptin: endocrine antagonists in fluid homeostasis

PT Manning, D Schwartz, NC Katsube, SW Holmberg, and P Needleman

Administration of pharmacological doses of arginine-vasopressin, related peptides, and other pressor agents induced a profound release of atriopeptin immunoreactivity into the circulation. The stimulated release of atriopeptin apparently was related to increased arterial blood pressure. Neither the nonpressor vasopressin analog 1-deamino-D-Arg8-vasopressin nor arginine-vasopressin in the presence of a specific pressor antagonist caused atriopeptin to be released into the circulation. Urine output was correlated with the level of atriopeptin released. Physiological levels of arginine-vasopressin suppress diuresis and produced vasoconstriction. Pharmacological levels of the hormone stimulated the cardiac endocrine system to release atriopeptin, which may cause diuresis and vasodilation to physiologically antagonize the effects of vasopressin.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Sodium Excretion in Response to Vasopressin and Selective Vasopressin Receptor Antagonists.
J. Perucca, D. G. Bichet, P. Bardoux, N. Bouby, and L. Bankir (2008)
J. Am. Soc. Nephrol. 19, 1721-1731
   Abstract »    Full Text »    PDF »
Key Amino Acids Located within the Transmembrane Domains 5 and 7 Account for the Pharmacological Specificity of the Human V1b Vasopressin Receptor.
S. Derick, A. Pena, T. Durroux, J. Wagnon, C. Serradeil-Le Gal, M. Hibert, D. Rognan, and G. Guillon (2004)
Mol. Endocrinol. 18, 2777-2789
   Abstract »    Full Text »    PDF »
[1-Deamino-4-Cyclohexylalanine] Arginine Vasopressin: A Potent and Specific Agonist for Vasopressin V1b Receptors.
S. Derick, L. L. Cheng, M. J. Voirol, S. Stoev, M. Giacomini, N. C. Wo, H. H. Szeto, M. Ben Mimoun, M. Andres, R. C. Gaillard, et al. (2002)
Endocrinology 143, 4655-4664
   Abstract »    Full Text »    PDF »
Physiological effects of vasopressin and atrial natriuretic peptide in the collecting duct.
T. Inoue, H. Nonoguchi, and K. Tomita (2001)
Cardiovasc Res 51, 470-480
   Abstract »    Full Text »    PDF »
Elevated Plasma Atrial Natriuretic Peptide Levels After Occlusion of the Thoracic Aorta.
H. Berkenstadt, T. Rosenthal, E. Peleg, E. Segal, A. Hackshaw, G. Ben-Ari, and A. Perel (1999)
Chest 115, 130-134
   Abstract »    Full Text »    PDF »
Mechanism of vasopressin natriuresis in the dog: role of vasopressin receptors and prostaglandins.
E. Kompanowska-Jezierska, C. Emmeluth, L. Grove, P. Christensen, J. Sadowski, and P. Bie (1998)
Am J Physiol Regulatory Integrative Comp Physiol 274, R1619-R1625
   Abstract »    Full Text »    PDF »
Low urine flow reduces the capacity to excrete a sodium load in humans.
G. Choukroun, F. Schmitt, F. Martinez, T. B. Drueke, and L. Bankir (1997)
Am J Physiol Regulatory Integrative Comp Physiol 273, R1726-R1733
   Abstract »    Full Text »    PDF »
Oxytocin releases atrial natriuretic peptide by combining with oxytocin receptors in the heart.
J. Gutkowska, M. Jankowski, C. Lambert, S. Mukaddam-Daher, H. H. Zingg, and S. M. McCann (1997)
PNAS 94, 11704-11709
   Abstract »    Full Text »    PDF »
Glucose Transporter (GLUT-4) Is Targeted to Secretory Granules in Rat Atrial Cardiomyocytes.
J. W. Slot, G. Garruti, S. Martin, V. Oorschot, G. Posthuma, E. W. Kraegen, R. Laybutt, G. Thibault, and D. E. James (1997)
J. Cell Biol. 137, 1243-1254
   Abstract »    Full Text »    PDF »
ELEVATED ARGININE VASOPRESSIN AND LOWERED ATRIAL NATRIURETIC FACTOR ASSOCIATED WITH HYPERTENSION IN COARCTATION OF THE AORTA.
J. M. Stewart, M. H. Gewitz, P. K. Woolf, F. Niguidula, B. G. Fish, and G. A. Zeballos (1995)
J. Thorac. Cardiovasc. Surg. 110, 900-908
   Abstract »    Full Text »
Circulating atrial natriuretic peptides in conscious rats: regulation of release by multiple factors.
R Eskay, Z Zukowska-Grojec, M Haass, J. Dave, and N Zamir (1986)
Science 232, 636-639
   Abstract »    PDF »
Inhibition of vasopressin action by atrial natriuretic factor.
M. Dillingham and R. Anderson (1986)
Science 231, 1572-1573
   Abstract »    PDF »
Vasopressin-stimulated release of atriopeptin: endocrine antagonists in fluid homeostasis.
P. Manning, D Schwartz, N. Katsube, S. Holmberg, and P Needleman (1985)
Science 229, 395-397
   Abstract »    PDF »
Ser-Leu-Arg-Arg-atriopeptin III: the major circulating form of atrial peptide.
D Schwartz, D. Geller, P. Manning, N. Siegel, K. Fok, C. Smith, and P Needleman (1985)
Science 229, 397-400
   Abstract »    PDF »
Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme.
W. Yan, F. Wu, J. Morser, and Q. Wu (2000)
PNAS 97, 8525-8529
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)